Interim report
Page 1
Evonile Pharma Limited (formerly known as Novartis India Limited) Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com November 03, 2026 To, The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub.: Integrated Filing (Financial) for the Quarter and half year ended September 30, 2026. Dear Sir/ Madam, Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD- 2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we hereby submit the Unaudited Financial Statements for the quarter and half year ended September 30, 2026, together with the Limited Review Report thereon (Annexures I and II), along with the other disclosures forming part of the Integrated Filing (Financial) for the quarter and half year ended September 30, 2026. This is for your information and records. Thanking You, For Evonile Pharma Limited (Formerly known as Novartis India Limited) Chandni Maru Company Secretary & Compliance Officer A60291 Encl: as above
Page 2
Evonile Pharma Limited (formerly known as Novartis India Limited) Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Integrated Filing (Financial) for the quarter and half year ended September 30, 2026. B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: Not Applicable C. Disclosure of Outstanding Default on Loans and Debt Securities: - Not Applicable Sr No. Particulars Amount (INR) 1. Loans / revolving facilities like cash credit from banks / financial institutions A. Total amount outstanding as on date 800 B. Of the total amount outstanding, amount of default as on date Nil 2. Unlisted debt securities i.e. NCDs and NCRPS - A. Total amount outstanding as on date - B. Of the total amount outstanding, amount of default as on date - 3. Total financial indebtedness of the listed entity including short-term and long-term debt 800 D. Disclosure of Related Party Transactions (Applicable only for Half Yearly Filings (i.e. 02nd and 04th Quarter): Annexure-III E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable Only for Annual Filing i.e. 4th Quarter): Not Applicable
Page 8
Evonile Pharma Limited (formerly known as Novartis India Limited) Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Annexure III S. N o Details of the counterparty Type of related party transacti on Value of the related party transac tion as approv ed by the audit commit tee/ Board for FY26 Value of transacti on during the reporting period QTD Sep'26 Value of transac tion during the reportin g period YTD Sep'26 Value of transa ction during the reporti ng period YTD Jun'26 In case amount are due to either party as a result of the transaction Name Name Relationshi p of the counterpar ty with the listed entity or its subsidiary QTD Sep'26 YTD Sep'26 YTD Jun'26 Openi ng balan ce Closing balance 1 Evonile Pharma Limited (Formely known as Novartis India Limited) Novartis AG - Upto 29th July 2026 Subsidiary Royalty 48.76 1.43 9.42 7.99 - 10.92 -8.48 2 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary NBS services 30.00 1.97 7.90 5.92 -2.23 -2.23 3 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary Business support services availed 66.00 20.06 34.67 14.61 -3.05 -25.51 4 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary Promotio nal and marketin g services 12.10 0.74 2.86 2.13 0.81 0.79 5 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary ESO services provided 41.00 0.42 6.97 6.55 3.05 0.45 6 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary Employe e balances transferr ed – payable 5.00 0.35 0.35 - - -0.24
Page 9
Evonile Pharma Limited (formerly known as Novartis India Limited) Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com 7 Novartis Healthcare Private Limited - Upto 29th July 2026 Subsidiary Employe e balances transferr ed – receivabl e 5.00 2.85 2.85 - - 0.00 8 Novartis India Limited Employees' Provident Fund Subsidiary Provident fund contributi on 120.00 0.47 2.18 1.70 - - 9 Novartis India Limited Superannuatio n Fund Subsidiary Superann uation contributi on 3.00 - - - - - 10 Novartis India Limited Gratuity fund Subsidiary Gratuity fund contributi on 23.00 - - - - 0.00 11 Novartis Pharma AG - Upto 29th July 2026 Subsidiary Purchase of stock in trade 3,000.0 0 97.80 526.57 428.77 - 293.3 2 -97.80 12 Novartis- Mitarbeiterbet eiligungsstiftu ng (MBS) - Upto 29th July 2026 Subsidiary ESOP / ESPP 10.00 - 0.06 0.06 -3.50 - To ta l 3363.86 126.09 593.83 467.74